Kezar Life Sciences, Inc.
KZRUnlisted companyKezar Life Sciences, Inc. in brief
Kezar Life Sciences, Inc. is an unlisted company in the Biotechnology industry, based in California, USA. It was founded in 2015. In the year to Dec 2021 it had sales of $0 M and a net loss of $54 M. It employs about 56 people.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
Kezar Life Sciences, Inc. timeline
- 2015
- 🏁· approximateFounded
- 2018
- 🔔· approximateInitial public offering on Nasdaq
Events of Kezar Life Sciences, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Kezar Life Sciences, Inc.
- Acquisitions and changes
- No longer listed: ticker KZR is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #3,828 (Jan 2020) · #3,096 (Jan 2021) · #2,864 (Jan 2022) · #2,665 (Dec 2022) · #3,812 (Jul 2023) · #3,936 (Jan 2024) · #2,136 (Mar 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -27.6%
- Liabilities / assets
- 9.7%
- Revenue per employee
- $0 K
- Profit per employee
- $-964 K
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-54 M
Dec-2021 ending year
Balance sheet
- Total assets
- $217 M
- Total liabilities
- $21 M
- Total equity
- $196 M
Dec-2021 ending year
Markets and events: Kezar Life Sciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-08 23:50 UTC, code D, resumed 04:00 UTC
- 2026-03-30 11:55 UTC, code T3, resumed 12:30 UTC
- 2025-10-16 20:01 UTC, code T3, resumed 20:25 UTC
Fails to deliver
- : 50,718 shares at $7.29
- : 35 shares at $7.29
- : 35 shares at $7.33
- : 628 shares at $6.70
- : 80 shares at $6.83
How Kezar Life Sciences, Inc. compares in Biotechnology
- Revenue$0 M · higher than 0% of 648
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kezar Life Sciences, Inc.🇺🇸 | $51 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Mar 8, 2026 (last known)
- Annual results:
- Dec-2021 ending year
- Balance sheet:
- Dec-2021 ending year
- Employees:
- As on 2021
- Profile updated:
- Nov 14, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kezar Life Sciences, Inc.? Verify and update this profile — free
Show Kezar Life Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.